Duration of Analgesia in Bier Block for Patients Undergoing Hand Surgery
Launched by MICHAEL BISHAY SHEHATA KEROLES · Oct 11, 2022
Trial Information
Current as of May 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a specific way to manage pain called a Bier block, which is a type of regional anesthesia used during hand surgeries. The goal is to see how long this method can effectively relieve pain for patients undergoing operations on their hands or arms. This technique is particularly useful for patients who cannot have general anesthesia due to health concerns.
To be eligible for this trial, participants should be between the ages of 18 and 65 and classified as ASA Grade 1 or 2, meaning they are generally healthy or have mild health issues. Unfortunately, those with more serious health conditions, such as severe heart or lung problems, certain neurological disorders, or those who have had issues with blood circulation, won't be able to participate. If you join the study, you can expect to receive the Bier block anesthesia during your surgery and be monitored for how well it works for pain relief. The trial is not yet recruiting, so there's still time to learn more about it before making a decision.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ASA Grade 1 \& 2
- Exclusion Criteria:
- • Patient refusal ASA Grade 3 \& 4 patients SEVERLY HYPOVOLEMIC STATE History of neurological. Reynauds disease, scleroderma, sickle cell anemia, myasthenia gravis, decompensated cardiac disease, diabetes mellitus, peptic ulcer, gastritis, and those with liver or renal insufficiency were excluded
About Michael Bishay Shehata Keroles
Michael Bishay Shehata Keroles is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a focus on ethical standards and regulatory compliance, he leads innovative studies that explore new therapeutic interventions across various medical fields. His expertise in trial design and execution, combined with a strong emphasis on patient safety and data integrity, positions him as a key contributor to the scientific community. Through collaboration with research institutions and healthcare professionals, Michael aims to foster breakthroughs that enhance the understanding and treatment of complex health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Assiut, , Egypt
Patients applied
Trial Officials
Michael Shehata, Resident
Principal Investigator
Assiut University
Eman Ismail, Professor
Study Director
Assiut University
Alaa Atia, Professor
Study Director
Assiut University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials